CRISPR up­start ticks off an­oth­er box on the IPO prep list as RA, SVB Leerink step in on a mega-raise

With 2020 set to bring the cur­tain down on a biotech IPO boom un­like any­thing we’ve seen be­fore, you have to won­der which com­pa­nies are set­ting the stage to try and fol­low up with their own S-1 in 2021. And Lo­can­abio may be in the mix af­ter to­day.

The San Diego-based biotech just brought in a mega-round, al­ways help­ful ahead of any IPO. In this case, that’s $100 mil­lion from a slate of in­vestors that’s adding groups with a well-known taste for IPO strate­gies: Vi­da Ven­tures, RA Cap­i­tal, In­vus, Acu­ta Cap­i­tal and an in­vest­ment arm of mar­ket mak­er SVB Leerink. Ra­jul Jain, an MD who had been on the ex­ec­u­tive team at Kite be­fore join­ing Vi­da with Arie Bellde­grun, is mov­ing to the Lo­can­abio board.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE